GSK plc
GSK
$37.56
$0.411.10%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.67B | 9.47B | 10.40B | 10.43B | 9.95B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.67B | 9.47B | 10.40B | 10.43B | 9.95B |
| Cost of Revenue | 2.88B | 2.42B | 3.25B | 3.03B | 2.59B |
| Gross Profit | 7.78B | 7.04B | 7.15B | 7.40B | 7.35B |
| SG&A Expenses | 2.80B | 2.59B | 3.36B | 4.90B | 2.80B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -371.36M | -226.71M | 153.68M | -248.55M | -264.92M |
| Total Operating Expenses | 7.37B | 6.55B | 9.12B | 9.56B | 6.94B |
| Operating Income | 3.30B | 2.91B | 1.28B | 867.97M | 3.01B |
| Income Before Tax | 2.52B | 2.65B | 721.01M | 83.28M | 1.89B |
| Income Tax Expenses | 321.94M | 423.18M | 79.40M | -1.30M | 240.95M |
| Earnings from Continuing Operations | 2.20B | 2.23B | 641.61M | 84.59M | 1.64B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -271.17M | -186.40M | -111.42M | -160.06M | -165.26M |
| Net Income | 1.93B | 2.05B | 530.19M | -75.48M | 1.48B |
| EBIT | 3.30B | 2.91B | 1.28B | 867.97M | 3.01B |
| EBITDA | 4.85B | 3.95B | 1.96B | 2.11B | 3.82B |
| EPS Basic | 0.47 | 0.50 | 0.13 | -0.02 | 0.36 |
| Normalized Basic EPS | 0.41 | 0.38 | 0.14 | 0.07 | 0.39 |
| EPS Diluted | 0.47 | 0.50 | 0.13 | -0.02 | 0.36 |
| Normalized Diluted EPS | 0.41 | 0.38 | 0.14 | 0.07 | 0.39 |
| Average Basic Shares Outstanding | 4.06B | 4.09B | 4.08B | 4.08B | 4.08B |
| Average Diluted Shares Outstanding | 4.11B | 4.14B | 4.15B | 4.14B | 4.12B |
| Dividend Per Share | 0.21 | 0.20 | 0.20 | 0.20 | 0.19 |
| Payout Ratio | 45.46% | 37.68% | 147.83% | -1,055.17% | 55.58% |